ALMIRALL S.A. -ANR-

Almirall reported net sales of €291.0m for Q1 2026, slightly below analysts’ expectations of €294.15m but up 2.2% year‑on‑year. The dermatology business in Europe drove growth, particularly biologics: Ebglyss doubled to €41.9m and Ilumetri grew 11.8% to €61.6m, with Ilumetri targeting peak sales of €300m. EBITDA was €67.5m with a margin of 23.2%; results were weighed down by higher license payments. Net debt to EBITDA remained very low at 0.1x. Management confirmed the 2026 guidance and highlighted pipeline building, partnerships and lifecycle management as growth levers, but still sees pressure on gross margins and challenges in the US market. » More on de.investing.com